



**Søren Galatius**

**Contact**

Søren Galatius

## Publications (4)

Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuillomenet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. *PLoS one* 2019; 14:e0210821.

Jeger R, Kaiser C, Galatius S, Rickli H, Pedrazzini G, Erne P, Eberli F, Bonetti P, Alber H, von Felten S, Sørensen R, Pfisterer M, BASKET and BASKET-PROVE investigators. Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. *Am Heart J* 2014; 168:698-705.

Jensen M, Galatius S, Pfisterer M, Erne P, De Servi S, Bertel O, Fahrni G, Zurek M, Rickli H, Soerensen R, Pedersen S, Jensen J, Iversen A, Wanitschek M, Alber H, Sandsten K, Kaiser C, BASKET-PROVE Investigators. Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial. *Int J Cardiol* 2013; 168:3802-6.

Jeger R, Gilgen N, Vuillomenet A, Jensen J, Rickli H, Pedrazzini G, Naber C, Galatius S, Eberli F, Alber H, Pfisterer M, Kaiser C. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. *Am Heart J* 2012; 163:136-41.e1.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)